News

Medicus Pharma Ltd. Advances Skin Cancer Treatment with Enrollment Success

Medicus Pharma Ltd. Advances Skin Cancer Treatment with Enrollment Success

Medicus Pharma Ltd. Successfully Completes Patient Enrollment for Phase 2 Study

Medicus Pharma Ltd. (NASDAQ: MDCX) is making significant strides in the field of biotechnology with the completion of patient enrollment for its Phase 2 clinical study, SKNJCT-003. This study aims to evaluate a groundbreaking non-invasive treatment for basal cell carcinoma (BCC) of the skin. With this advancement, the Company is setting its sights on bringing a promising therapeutic option to patients facing this common skin cancer.

Overview of SKNJCT-003 Clinical Study

The Phase 2 clinical trial, SKNJCT-003, involves a randomized, double-blind, placebo-controlled design and will assess the safety and efficacy of Doxorubicin Microneedle Array (D-MNA) in treating patients with nodular BCC. A total of ninety (90) patients have been enrolled across various clinical sites in the United States, showing a robust commitment to advancing patient care.

Anticipated Results and Next Steps

The Company is eager to announce that topline results from the SKNJCT-003 study are expected to be released in the first quarter of 2026. Alongside this, Medicus intends to request an End-of-Phase 2 (EOP2) meeting with the FDA within the first half of 2026, aiming to solidify its path forward in the regulatory process.

Insights from Company Leadership

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, expressed optimism regarding the trial's progress, indicating that defeating basal cell carcinoma could represent an immense market opportunity, estimated at approximately $2 billion. He noted the encouraging results from a preliminary interim data analysis, which showed over 60% clinical clearance among patients, showcasing the potential efficacy of D-MNA in treating this condition.

Understanding the Clinical Trial Design

As a well-structured clinical study, SKNJCT-003 is set up to evaluate two different dosage levels of D-MNA compared to a placebo control. Patients are randomly assigned to one of three groups: the placebo group, a low-dose group receiving 100?g of D-MNA, and a high-dose group receiving the maximum dose of 200?g. This design allows for a thorough assessment of the safety and effectiveness of the treatment.

Previous Study Successes and Progress

The preliminary findings from the earlier Phase 1 study (SKNJCT-001) have provided a solid foundation for the current trial. That study reported no serious adverse events and highlighted the tolerability of D-MNA across all dose levels. Such positive outcomes reinforce the belief in the potential of microneedle technology in effectively treating BCC.

Future Directions and Global Impact

In addition to the advancements in the SKNJCT-003 study, Medicus Pharma Ltd. has expanded its research efforts globally. Notably, the Company is moving forward with a new trial (SKNJCT-004) in the UAE, which demonstrates its commitment to bringing innovative treatment options to patients worldwide.

Strategic Collaborations and Partnerships

Medicus has accelerated its innovation potential through collaborative efforts, including a recent partnership with the Gorlin Syndrome Alliance. This collaboration aims to improve access for patients suffering from Gorlin Syndrome, emphasizing the Company’s dedication to advocacy and enhanced patient care.

Conclusion: A Bright Future for Medically Innovative Solutions

With the completion of patient enrollment in the SKNJCT-003 clinical study, Medicus Pharma Ltd. stands on the brink of potentially revolutionizing the approach to treating basal cell carcinoma. This critical phase presents exciting opportunities for patients and reflects the Company's unwavering commitment to developing innovative and effective therapeutic solutions. The expected results in 2026 could mark significant advancements not only for the Company but also for the numerous patients in need of effective treatments.

Frequently Asked Questions

What is the purpose of the SKNJCT-003 study?

The SKNJCT-003 study aims to evaluate the safety and efficacy of Doxorubicin Microneedle Array (D-MNA) as a non-invasive treatment for nodular basal cell carcinoma.

How many patients were enrolled in the trial?

The trial successfully enrolled ninety (90) patients at clinical sites across the United States.

When are the results from the study expected to be published?

Topline results are anticipated to be released in the first quarter of 2026.

What type of trial design is being used for this study?

The study employs a randomized, double-blind, placebo-controlled design to ensure accurate evaluation of treatment effects.

What previous study supports the current clinical trial?

The current trial is supported by results from the Phase 1 study (SKNJCT-001) which demonstrated safety and tolerability of the treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 287

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 15

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 102

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 164

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

Embracing Harmony and Cooperation in Today's World

Updated Category News Views 99

Understanding the Essence of Hehe Culture The concept of "Hehe" in Chinese culture symbolizes harmony, peace, and cooperation, deeply embedded in the collective mindset. This philosophy, with roots extending over thousands of years, emphasizes living in balance not only with one another but also with nature and oneself. The teachings of Hehe are particularly significant...

Continue Reading
Current Trends in Mortgage Rates and Home Buying Activity

Updated Category News Views 184

The average rate for a 30-year fixed-rate mortgage dropped to 6.08% in 2024, hitting its lowest point in two years. This slight decrease from 6.09% the previous week caught the eye of potential home buyers and homeowners considering refinancing. In contrast, the average rate for a 15-year mortgage ticked up by a single basis point to reach 5.16%. These small fluctuations...

Continue Reading
Mueller Water Products Engages at 2024 Baird Industrial Conference

Updated Category News Views 195

Mueller Water Products to Engage in the Baird Industrial Conference Mueller Water Products, Inc. (NYSE: MWA), headquartered in Atlanta, is set to participate in the Baird 2024 Global Industrial Conference. This prestigious event will take place in a vibrant city known for its industrial drive and innovation. Mueller’s management team is looking forward to sharing...

Continue Reading
SANY Showcases Advanced Eco-Friendly Solutions at bauma

Updated Category News Views 389

SANY Showcases Advanced Eco-Friendly Solutions at bauma The 34th bauma, recognized as the world's leading trade fair for construction machinery, recently wrapped up in Munich. This year's theme was "The World of Efficiency, Your Partner to Create the Best", and SANY Group, in collaboration with Putzmeister, put forth an impressive display of cutting-edge technology and...

Continue Reading
Orbit International Corp Completes $1 Million Power Supply Order

Updated Category News Views 182

Orbit International Corp Secures Major Follow-On Order Orbit International Corp. (OTCID Basic Market: ORBT), a prominent player in electronic manufacturing and software solutions, has announced the receipt of a new order valued at approximately $1,000,000. This order, secured by its Orbit Power Group (OPG), pertains to a commercial power supply that is utilized in...

Continue Reading